Jim Lambert PhD

Associate Research Professor of Pathology, CU Anschutz, President & Founder, Vona Oncology

Dr. Lambert is an Associate Professor of Research in the department of Pathology and has over 30 years of experience in cancer research. He is the founder and president of Vona Oncology, a start-up biopharma company from the University of Colorado Anschutz Medical Campus. His research team has spearheaded the efforts to develop novel small molecule drugs as viable clinical candidates for aggressive cancers such as triple-negative breast cancer, ovarian cancer and melanoma. Vona Oncology’s lead compound, VDX-431, has shown strong efficacy, both in vitro and in vivo, in killing cancer cells and tumors. Vona Oncology has been awarded an NIH NCI SBIR Fast-Track award for moving VDX-431 toward clinical trials for triple-negative breast cancer.  Vona Oncology is also the recipient of a State of Colorado Office of Economic Development and International Trade Advanced Industry Accelerator Early-Stage Capital Retention grant to further business development of Vona Oncology. 

Cooley Sponsor Logo
CO Office of Economic Development Logo Horizontal

Reservation Policy & Attendance Limit: This event has an attendance limit of 300 people and seats will be reserved on a first-come, first-served basis. Please be sure to register as soon as possible to reserve your seat and ensure your attendance. 

*We strive to be inclusive. All are welcome to attend!

CU Innovations

CU Anschutz

Anschutz Health Sciences Building

1890 N Revere Ct

Suite 6202

Mail Stop F411

Aurora, CO 80045


CMS Login